If your child has been diagnosed with myopia, you face an important decision about which treatment will work best for your family. Both Stellest lenses and low-dose atropine are proven treatments that slow myopia progression. Neither is universally better than the other. The right choice depends on your child's age, lifestyle, prescription, and your family's preferences.
Stellest lenses use H.A.L.T. (Highly Aspherical Lenslet Target) technology to slow myopia progression through optical means. The lens features a clear central zone for normal vision, surrounded by 1,021 tiny aspherical lenslets arranged in 11 concentric rings. These lenslets create a controlled volume of light in front of the retina, sending a signal to the eye to slow its elongation. Your child looks through the clear center for all activities while the technology works in the background.
Stellest lenses received FDA authorization in September 2025, making them the first FDA-authorized eyeglass lenses designed to help slow myopia progression in children. They look like regular glasses, and your child will not notice the lenslets or experience visual disturbances. The lenses provide vision correction and myopia control in a single solution.
Low-dose atropine works through pharmacological means, using medication to affect the biochemistry of eye growth. Atropine is an anticholinergic blocking agent that slows the axial elongation of the eye. The treatment involves applying eye drops nightly, typically at concentrations between 0.01% and 0.05%. Research over the past 20 years has established ultra-low doses as safe and effective for myopia control in children.
Unlike Stellest, atropine does not provide vision correction. Children typically wear regular single-vision glasses during the day for clear vision, then apply the eye drops at night for myopia control. This means two separate interventions rather than a single solution.
Evidence supporting Stellest comes from a U.S. randomized, double-masked clinical trial involving children aged 6 to 12 years. Over two years, children wearing Stellest lenses showed 71% less refractive progression and 53% less axial elongation compared with children wearing standard single-vision lenses. Axial elongation is the physical lengthening of the eyeball that drives disease risks associated with myopia.
In practical terms, if a child would typically progress by 1.00 diopter per year without treatment, Stellest could reduce that to approximately 0.30 diopters per year. Over five years of childhood growth, that could mean accumulating 1.50 diopters versus 5.00 diopters, potentially reducing lifetime risk of vision complications.
Research on low-dose atropine demonstrates varying levels of myopia control depending on concentration. The LAMP Study, a randomized, double-masked trial with 438 children ages 4 to 12, showed that 0.05% atropine reduced progression by approximately 50% over two years. Lower concentrations of 0.025% and 0.01% showed progressively lower efficacy. Higher concentrations within the low-dose range (0.05%) provide myopia control that approaches the effectiveness of Stellest lenses.
Stellest fits into existing morning routines. Your child simply puts on their glasses when they wake up and wears them throughout the day, just like regular glasses. The treatment requires no special procedures, no medication administration, and no complex hygiene protocols. Consistency is important. Children should wear Stellest lenses throughout waking hours for maximum effectiveness.
Stellest lenses are designed with durability in mind, making them suitable for active play, school activities, and most sports. The lenses require the same basic care as any eyeglasses: daily cleaning with lens cleaner spray and a microfiber cloth, storage in a protective case when not wearing them, and regular professional adjustments every few months.
Atropine requires a nightly medication routine. Parents typically supervise the eye drop application, especially initially, to ensure proper technique. The child tilts their head back, and one drop is instilled in each eye before bedtime. The process takes just a minute or two, but it requires consistency.
During the day, children wear regular single-vision glasses for vision correction. The atropine works in the background, slowing the signals that cause eye elongation. For some families, this separation of vision correction and myopia control feels more complex. For other families, a quick nightly eye drop feels simpler than ensuring consistent all-day glasses wear.
Stellest lenses have minimal side effects because they work through optical means rather than medication. Children experience no systemic effects, no light sensitivity, and no changes to their eyes beyond the intended slowing of progression. Some children notice a brief adaptation period as their eyes adjust to the new optical design, but this typically resolves within days.
The primary limitation is that effectiveness depends entirely on wear time. If your child forgets their glasses or refuses to wear them, the treatment cannot work. Consistent all-day wear is essential for results.
At ultra-low doses (0.01% to 0.05%), atropine has minimal side effects. A 2021 clinical trial of 400 children over 2 years found that approximately 23% to 24% of children experienced mild photophobia (light sensitivity) in bright sunlight during the first year. No discomfort occurred in normal indoor or daily outdoor light, and the photophobia was easily resolved by wearing sunglasses or sun hats during outdoor activities.
By the second year, side effects decreased significantly. No serious adverse events or allergic reactions were reported. The key finding is that side effects, when they occur, are mild and manageable.
Stellest lenses tend to work well for certain children and families.
Atropine may be a better fit for other children and families.
Stellest offers daytime convenience with no nightly routines. Once your child puts on their glasses in the morning, treatment is happening automatically throughout the day. There is no medication to remember, no timing to worry about, no supplies to reorder. The challenge is ensuring consistent all-day wear.
Atropine offers nighttime convenience with minimal daytime impact. The medication administration takes just a minute or two before bed. However, parents must remember the nightly routine, keep the medication properly stored, and ensure they do not run out of drops.
Both treatments require similar monitoring schedules. Comprehensive evaluations every six months track visual acuity, eye health, and axial length measurements. With Stellest, the focus is on assessing wear-time compliance and optical effectiveness. With atropine, the focus is on monitoring medication response and any side effects. Our children's vision symptom checker can also help you track signs of progression between visits.
For some children, combining Stellest lenses with low-dose atropine provides maximum myopia control. This combination approach is typically recommended for rapid progressors advancing faster than 1.00 diopter per year, children with very strong family history of high myopia, or kids showing inadequate response to a single treatment despite good compliance.
Combination therapy addresses myopia progression through two different mechanisms simultaneously: optical control through Stellest technology and pharmacological control through atropine. Research suggests that combining treatments may provide additive benefits for children at highest risk of developing high myopia.
The decision to use combination therapy depends on your child's age, current prescription, rate of progression, growth patterns, and response to initial treatment. Your eye care team will discuss whether combination therapy makes sense for your child's specific situation.
At Insight Vision Center Optometry, our clinical team offers training in all four myopia management modalities: Stellest, orthokeratology, MiSight contact lenses, and atropine. This breadth of knowledge means our treatment recommendations are truly individualized rather than limited to a single option.
Dr. Thanh Mai, OD, FSLS serves as VP of Clinical Innovation for Treehouse Eyes and sits on the EssilorLuxottica advisory board for Stellest. Dr. Nathan Schramm, OD, FSLS, FBCLA serves as principal investigator for the Euclid Phoenix ortho-k trial and has presented at AAOMC conferences. Dr. Ariel Chen, OD serves as co-investigator on the Euclid Phoenix trial and manages ortho-k and atropine protocols. Dr. Valerie Lam, OD, FAAO, FOVDR brings pediatric myopia and vision therapy integration knowledge. Dr. Nhi Nguyen, OD is affiliated with Treehouse Eyes and provides ortho-k care.
Our practice uses the Zeiss AXL WAVE Optical Biometer and Pentacam for precise axial length tracking and corneal measurements. Accurate baseline and follow-up measurements help us monitor your child's response to treatment and adjust the approach when needed.
Earlier intervention generally provides more benefit because it allows more years of controlled progression during the peak growth period. Stellest is FDA-authorized for children ages 6 to 12. Atropine can sometimes be used in younger children under age 6 when other treatments are not yet appropriate. Your eye doctor will recommend the best timing based on your child's specific situation.
Yes, Stellest lenses are designed for active children and work well for most sports, school activities, and active play. For high-impact contact sports, your eye care team may recommend protective sports eyewear or discuss alternative arrangements during games and practices.
Missing an occasional dose is not a major concern. Simply resume the regular schedule the next night. However, consistent nightly use provides the best results. If frequent missed doses are becoming a pattern, discuss this with your eye care team, as a different treatment approach might work better for your family.
Most children continue myopia management treatment throughout their growth years, typically until ages 16 to 18 or until progression has stabilized. Treatment duration varies based on individual factors including age at onset, rate of progression, and family history. Regular monitoring helps determine when treatment can safely be reduced or stopped.
Myopia management treatments slow progression but typically do not stop it completely. Your child may still experience some prescription increases over time, but the changes should be smaller than they would be without treatment. The goal is to limit the total amount of myopia that develops.
Your eye care team monitors treatment effectiveness through regular evaluations that include refraction measurements and axial length tracking. Slower progression compared to expected rates, and stable or reduced rate of eye elongation, indicate the treatment is working. If response is inadequate, adjustments to the treatment plan can be made.
